 
 
EXPLANATION:  CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW . 
        [Brackets ] indicate matter deleted from existing law.  
         Underlining  indicates amendments to bill.  
         Strike out  indicates matter stricken from the bill by amendment or deleted from the law by 
amendment.             *hb1087*      
HOUSE BILL 1087  
J5, J4    5lr3160  
    CF SB 921  
By: Delegates Bhandari and Woods , Woods, Alston, Bagnall , Chisholm, Cullison, 
Guzzone, Hill, Hutchinson, S.  Johnson, Kaiser, Kerr, Kipke, Lopez, 
Martinez, M.  Morgan, Pena –Melnyk, Reilly, Rosenberg, Ross, Szeliga, 
Taveras, White  Holland, and Woorman  
Introduced and read first time: February 5, 2025  
Assigned to:  Health and Government Operations  
Committee Report: Favorable with amendments  
House action: Adopted  
Read second time: March 6, 2025  
 
CHAPTER ______  
 
AN ACT concerning  1 
 
Health Insurance – Step Therapy or Fail –First Protocols – Drugs to Treat 2 
Associated Conditions of Advanced Metastatic Cancer  3 
 
FOR the purpose of prohibiting certain insurers, nonprofit health service plans, and health 4 
maintenance organizations from imposing a step therapy or fail –first protocol on 5 
certain prescription drugs used prescribed by a treating physician  to treat a 6 
symptom of or a side effect from treatment of certain metastatic cancer under certain 7 
circumstances; and generally relating to step therapy and fail –first protocols and 8 
health insurance.  9 
 
BY repealing and reenacting, without amendments,  10 
 Article – Insurance  11 
Section 15 –142(a)(1) and (4) and (b)  12 
 Annotated Code of Maryland  13 
 (2017 Replacement Volume and 2024 Supplement)  14 
 
BY repealing and reenacting, with amendments,  15 
 Article – Insurance  16 
Section 15 –142(e)  17 
 Annotated Code of Maryland  18 
 (2017 Replacement Volume and 2024 Supplement)  19 
 
2 HOUSE BILL 1087   
 
  SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 1 
That the Laws of Maryland read as follows:  2 
 
Article – Insurance  3 
 
15–142. 4 
 
 (a) (1) In this section the following words  have the meanings indicated.  5 
 
  (4) (i) “Step therapy or fail –first protocol” means a protocol established 6 
by an insurer, a nonprofit health service plan, or a health maintenance organization that 7 
requires a prescription drug or sequence of prescription d rugs to be used by an insured or 8 
an enrollee before a prescription drug ordered by a prescriber for the insured or the enrollee 9 
is covered.  10 
 
   (ii) “Step therapy or fail –first protocol” includes a protocol that 11 
meets the definition under subparagraph (i) of this paragraph regardless of the name, label, 12 
or terminology used by the insurer, nonprofit health service plan, or health maintenance 13 
organization to identify the protocol.  14 
 
 (b) (1) This section applies to:  15 
 
   (i) insurers and nonprofit health servic e plans that provide hospital, 16 
medical, or surgical benefits to individuals or groups on an expense –incurred basis under 17 
health insurance policies or contracts that are issued or delivered in the State; and  18 
 
   (ii) health maintenance organizations that pr ovide hospital, 19 
medical, or surgical benefits to individuals or groups under contracts that are issued or 20 
delivered in the State.  21 
 
  (2) An insurer, a nonprofit health service plan, or a health maintenance 22 
organization that provides coverage for prescripti on drugs through a pharmacy benefits 23 
manager is subject to the requirements of this section.  24 
 
 (e) An entity subject to this section may not impose a step therapy or fail –first 25 
protocol on an insured or an enrollee for a prescription drug approved by the U .S. Food and 26 
Drug Administration if:  27 
 
  (1) (I) the prescription drug is used to treat the insured’s or enrollee’s 28 
stage four advanced metastatic cancer; and  29 
 
  [(2)] (II) use of the prescription drug is:  30 
 
   [(i)] 1. consistent with the U.S. Food and Drug  31 
Administration –approved indication or the National Comprehensive Cancer Network 32 
Drugs & Biologics Compendium indication for the treatment of stage four advanced 33 
metastatic cancer; and  34 
 HOUSE BILL 1087  3 
 
  
   [(ii)] 2. supported by peer –reviewed medical literature ; OR 1 
 
  (2) (I) THE PRESCRIPTION DRU G IS USED  PRESCRIBED BY A 2 
TREATING PHYSICIAN  TO TREAT A SYMPTOM O F OR A SIDE EFFECT F ROM 3 
TREATMENT OF THE INS URED’S OR ENROLLEE ’S STAGE FOUR ADVANCE D 4 
METASTATIC CANCER THAT THE TREATING PR OVIDE R DETERMINES WILL 5 
NEGATIVELY IMPACT TH E INSURED ’S OR ENROLLEE ’S HEALTH IF  LEFT UNTREATED ; 6 
AND  7 
 
   (II) USE OF THE PRESCRIPT ION DRUG IS : 8 
 
    1. CONSISTENT WITH BEST  PRACTICES FOR THE 9 
TREATMENT OF STAGE F OUR ADVANCED METASTA TIC CANCER , A CONDITION 10 
ASSOCIATE D WITH STAGE FOUR AD VANCED METASTATIC CA NCER , OR A SIDE EFFECT 11 
ASSOCIATED WITH STAG E FOUR ADVANCED META STATIC CANCER TREATM ENT; AND 12 
 
    2. SUPPORTED BY PEER –REVIEWED MEDICAL 13 
LITERATURE ; AND 14 
 
   (III) THE PRESCRIPTION DRU G IS COVERED UNDER T HE TERMS 15 
OF THE  POLICY OR CONTRACT O F THE INSURED OR ENR OLLEE . 16 
 
 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall apply to all 17 
policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or 18 
after January 1, 2026.  19 
 
 SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall take effect 20 
January 1, 2026.  21 
 
 
 
 
Approved:  
________________________________ ________________________________ ________________   
           Governor.  
________________________________ ________________________________ ________________   
         Speaker of the House of Delegates.  
________________________________ ________________________________ ________________   
                 President of the Senate.  